Basel evolved from a silk dyeing industry hub in the 18th century to a chemical to a life sciences hub. What’s next?
"Ordering your drugs on Amazon and paying for them with bitcoins.”
At BaselArea.swiss’ 5th annual event during JPMorgan Healthcare week in San Francisco, we discussed the digital evolution in biotech and pharma.
The panel included experts from big pharma (Miro Venturi, Global Head Diagnostics Biomarkers & Personalized Healthcare at Roche), Artificial Intelligence (Kailash Swarna, Global Head Pharma Solutions at Datavant, a Roivant-family company), from the transaction side (Jason Moran, Managing Director & Head Life Sciences Group, KPMG) as well as a Swiss femtech founder and 30under30 Forbes 2018 Award winner (Lea von Bidder, Founder and President, Ava Sciences).
A lively discussion moderated by Patrik Frei (CEO, Venture Valuation) circled around data-driven and patient-centered business models: There is no shortage of data, but the big question is how to monetize data? How to improve the patient journey and moving to a B2C model? And how does digital patient recruitment for clinical trials look like?
The panel agreed that in the future we will see more partnerships and collaborations among the different players – big pharma, tech start-ups, consumer-facing companies, data specialists, and traditional life sciences companies.
Basel as a location remains at the forefront of healthcare innovation during this crucial next phase – the digital transformation of healthcare. All pieces are in place in Basel’s ecosystem for digital medicines: A diverse workforce comprised of traditional pharma and tech talent, a pool of over 700 life sciences and tech companies and a business-friendly working environment.